SIP
ESPR

Stoneridge Investment Partners’s Esperion Therapeutics ESPR Stock Holding History

Stoneridge Investment Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58K Buy
+18,237
New +$51K 0.04% 143
2024
Q4 		– Sell
-117,958
Closed -$195K – 151
2024
Q3 		$195K Hold
117,958
– – 0.07% 94
2024
Q2 		$262K Buy
117,958
+24,557
+26% +$57.8K 0.1% 97
2024
Q1 		$250K Buy
93,401
+64,145
+219% +$156K 0.1% 95
2023
Q4 		$87K Hold
29,256
– – 0.04% 88
2023
Q3 		$29K Hold
29,256
– – 0.01% 99
2023
Q2 		$41K Buy
+29,256
New +$40.9K 0.02% 106

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Stoneridge Investment Partners's ESPR Position: Q2 2026 in Review

Stoneridge Investment Partners opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 18,237 shares worth $58K. The stake represents 0.04% of the portfolio and ranks #143 among its holdings. This is a return to the name: Stoneridge Investment Partners previously reported a position in ESPR as recently as Q3 2024.

Stoneridge Investment Partners first reported a position in ESPR in Q2 2023 and has held it in 7 quarters since. The position peaked at $262K in Q2 2024. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Stoneridge Investment Partners held 18,237 shares of Esperion Therapeutics worth $58K as of Q2 2026.
  • Esperion Therapeutics was a new Stoneridge Investment Partners position in Q2 2026.
  • Esperion Therapeutics made up 0.04% of Stoneridge Investment Partners's portfolio in Q2 2026, its #143 holding.
  • Stoneridge Investment Partners first reported a position in Esperion Therapeutics in Q2 2023 and has held it in 7 quarters since.
  • Stoneridge Investment Partners's Esperion Therapeutics position peaked at $262K in Q2 2024.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.